The company is a national provider of compounded pharmaceutical prescriptions that leads with a focus on innovation, patient outcomes, and integrity. The company develops relationships with doctors who have patients with difficult-to-treat conditions and provides individualized treatments that in many cases produce life-changing results. The company offers a wide variety of compounded medications including but not limited to HRT (Hormone Replacement Therapy), analgesics, veterinary, anti-infective, oncology, and numerous other drug classes.
The company is led by a team of industry-renowned experts who have owned, grown, acquired, and sold compounding pharmacies over decades of experience in the space.
The company plans to deploy an aggressive acquisition strategy to expand its national footprint. The team is interested in partnering with 503A compounding pharmacy owners who have interest in selling a majority stake in their business to be part of a scalable, PE-backed platform with significant growth opportunities.